ClinicalTrials.gg
TerminatedNCT03251326Updated Jul 15, 2022Results posted

Nabilone in Cannabis Users With PTSD

A Phase 1/2 interventional study of Nabilone and Cannabis in Cannabis and Post Traumatic Stress Disorder, sponsored by New York State Psychiatric Institute. Terminated at 1 site in United States. Open to participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by New York State Psychiatric Institute · Phase 1/2, Interventional, and Basic science

Why this study was terminated
Recruitment difficulties

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Oct 2015, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
1,414th of 1,491
4 · median 65
Started
2015
with 58 others
Phase 1/2
35 of 1,664
3 open now
Registered
795th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 1,414th largest by enrollment of the 1,491 interventional ones that give a count, is one of 59 that started in 2015, is one of 35 in phase 1/2, and was the 795th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 203 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 21 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

Despite the prevalence of cannabis use among the PTSD population and self-reports that it is used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are unknown. The purpose of this placebo-controlled, within-subject study is to assess the effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in cannabis smokers with PTSD.

Read the detailed description

This study will compare the effects of smoked cannabis and nabilone on attentional bias toward trauma- related stimuli, subjective and emotional processing to a range of trauma-and non-trauma-related images and physiological reactivity to these stimuli in individuals with CUD and PTSD. Importantly, this study will also probe the abuse related potential of nabilone compared to smoked cannabis in this population, a critical aspect in determining the potential feasibility for its use clinically to treat CUD in PTSD populations. The effects of nabilone will be compared to propranolol as a positive control.

03

Conditions studied

  • Cannabis
  • Post Traumatic Stress Disorder
04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current cannabis use
  • PTSD symptoms
  • Able to give and comply with study procedures
  • Women who are normally cycling and practicing an effective form of other than hormonal contraceptives

Exclusion criteria

Exclusion Criteria:

  • Meeting criteria for certain current psychiatric disorders
  • Clinical laboratory tests outside of normal limits
  • History of cardiac or respiratory diagnoses
  • Current parole or probation
  • Women who are currently pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Nabilone

    Nabilone capsules (4 mg)

    Drug: Nabilone

  • Active comparator
    Propranolol

    Propranolol capsules (40mg)

    Drug: Propranolol

  • Experimental
    Smoked cannabis

    (0.0 and 5.6% THC)

    Drug: Cannabis

  • Placebo comparator
    Placebo

    Placebo capsules

    Drug: Placebo

Interventions

  • Nabilone capsules (4 mg)

  • Cigarettes (0.0 and 5.6% THC)

  • Propranolol capsules (40mg)

  • DrugPlacebo

    Placebo capsules

06

What researchers measure

Primary outcomes

  1. Cue Reactivity (Emotional Stroop Task)

    We cannot provide data as the study was terminated due to lack of feasibility. The staff responsible for data collection, organization, and cleaning have left the institution; we have made every effort to locate the data for the two participants who completed the study, but have been unsuccessful. We do not have access to the data.

    Time frame: 1 month

07

Results

Posted Oct 12, 2020

Participant flow

Participant flow — Overall Study
MilestoneActive Nab > Plac Prop > Plac CannPlac Nab > Act Prop > Plac CannPlac Nab > Plac Prop > Act CannPlac Nab > Plac Prop > Plac Cann
Started1111
Completed1100
Not completed0011

Outcome measures

PrimaryCue Reactivity (Emotional Stroop Task)

We cannot provide data as the study was terminated due to lack of feasibility. The staff responsible for data collection, organization, and cleaning have left the institution; we have made every effort to locate the data for the two participants who completed the study, but have been unsuccessful. We do not have access to the data.

Time frame:
1 month

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were collected throughout the duration of the study (October 2015 - June 2019). Each participant's was enrolled in the study for approximately 1.5 months, during which adverse event data was collected (baseline through each of 4 experimental sessions).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Nab > Plac Prop > Plac Cann———
Plac Nab > Act Prop > Plac Cann———
Plac Nab > Plac Prop > Act Cann———
Plac Nab > Plac Prop > Plac Cann———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nabilone/Propranolol/Placebo + Smoked Cannabis/Placebo Placebo
<=18 years0
Between 18 and 65 years2
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Nabilone/Propranolol/Placebo + Smoked Cannabis/Placebo Placebo
Female0
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nabilone/Propranolol/Placebo + Smoked Cannabis/Placebo Placebo
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Nabilone/Propranolol/Placebo + Smoked Cannabis/Placebo Placebo
United States2
08

Study locations

1 site
  • New York State Psychiatric Institute
    New York, New York 10032, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Jun 2019, 44 months.

Results were first posted in Oct 2020, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 16, 2017
StartActual
Oct 2015
Primary completionActual
Jun 2019
CompletionActual
Jun 2019
Results first posted
Oct 12, 2020
Last update
Jul 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03251326
Responsible party
Margaret Haney (Professor of Neurobiology (in Psychiatry) at CUMC, New York State Psychiatric Institute) — Principal investigator
First posted
Aug 16, 2017
Start date
Oct 2015
Primary completion
Jun 2019
Completion
Jun 2019
Results posted
Oct 12, 2020
Last update
Jul 15, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nabilone · Cannabis sativa subsp. indica TOP

Start the discussion